{"news_desk": "Editorial", "print_page": "24", "section_name": "Opinion", "subsection_name": null, "byline": {"original": "By THE EDITORIAL BOARD", "person": [], "organization": "THE EDITORIAL BOARD"}, "abstract": "Editorial warns that powerful drugs recently approved to treat Hepatitis C, disease which killed 20,000 Americans in 2013, might become too expensive for insurers to offer; cites drugs like Sovaldi, which can cost around $1000 per pill; criticizes state Medicaid programs' efforts to reduce costs by restricting availability, and encourages insurers to continue pressing for discounts.", "type_of_material": "Editorial", "word_count": "526", "lead_paragraph": "Competition and discounts are going a long way toward resolving the problem of expensive hepatitis C drugs.", "pub_date": "2015-09-02T00:00:00Z", "document_type": "article", "slideshow_credits": null, "headline": {"main": "Costly Hepatitis C Drugs for Everyone?", "content_kicker": "Editorial", "print_headline": "Costly Hepatitis C Drugs for Everyone?", "kicker": "Editorial"}, "snippet": "Competition and discounts are going a long way toward resolving the problem of expensive hepatitis C drugs.", "multimedia": [{"height": 126, "url": "images/2015/09/02/opinion/02wed2/02wed2-thumbWide.jpg", "legacy": {"widewidth": "190", "wideheight": "126", "wide": "images/2015/09/02/opinion/02wed2/02wed2-thumbWide.jpg"}, "type": "image", "width": 190, "subtype": "wide"}, {"height": 746, "url": "images/2015/09/02/opinion/02wed2/02wed2-articleLarge.jpg", "legacy": {"xlargewidth": "600", "xlargeheight": "746", "xlarge": "images/2015/09/02/opinion/02wed2/02wed2-articleLarge.jpg"}, "type": "image", "width": 600, "subtype": "xlarge"}, {"height": 75, "url": "images/2015/09/02/opinion/02wed2/02wed2-thumbStandard.jpg", "legacy": {"thumbnailwidth": "75", "thumbnail": "images/2015/09/02/opinion/02wed2/02wed2-thumbStandard.jpg", "thumbnailheight": "75"}, "type": "image", "width": 75, "subtype": "thumbnail"}], "web_url": "http://www.nytimes.com/2015/09/02/opinion/costly-hepatitis-c-drugs-for-everyone.html", "keywords": [{"rank": "1", "is_major": "Y", "value": "Editorials", "name": "subject"}, {"rank": "2", "is_major": "Y", "value": "Drugs (Pharmaceuticals)", "name": "subject"}, {"rank": "3", "is_major": "N", "value": "Harvoni (Drug)", "name": "subject"}, {"rank": "4", "is_major": "N", "value": "Sovaldi (Drug)", "name": "subject"}, {"rank": "5", "is_major": "N", "value": "Medicaid", "name": "subject"}, {"rank": "6", "is_major": "N", "value": "Gilead Sciences Inc", "name": "organizations"}, {"rank": "7", "is_major": "Y", "value": "Hepatitis", "name": "subject"}], "blog": [], "_id": "55e6a36238f0d86bbc6506db", "source": "The New York Times"}